symptomatic COVID-19 – Communicable Diseases Research

Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19

코로나19 중증도에 따라 항체 표적 SARS-CoV-2 에피토프 레퍼토리 달라

Article

Published on 2022-12-012022-09-11
Journal: Virulence
[Category] COVID19(2023년), SARS, 진단, 치료법,

Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19

이미 COVID-19에 걸린 사람에 대한 코로나바이러스 질병 2019(COVID-19) 예방 접종의 필요성

Article

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat
[Category] SARS, 변종,

Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years – United States, July 2022

18세 이상인 사람의 Novavax COVID-19 백신 사용에 대한 예방접종 관행에 대한 자문 위원회의 임시 권고 - 미국, 2022년 7월

Article

Published on 2022-08-052022-09-11
Journal: Morbidity and Mortality Weekly Report
[Category] SARS, 변종,

[키워드] 95% CI Administered Adults Alpha variant assessments association authorization B.1.1.7 causal relationship cause Chain Reaction circulating Committee COVID-19 COVID-19 vaccine dose drug Efficacy efficacy analysis Emergency Emergency use authorization EUA FDA flexibility food Food and Drug Administration immunization infection with SARS-CoV-2 information Interim Matrix-M myocarditis Novavax NVX-CoV2373 per-protocol Pericarditis Person polymerase chain reaction Practice predominant PROTECT Protein provide reported reverse transcription Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 symptomatic symptomatic COVID-19 United States vaccination Vaccine vaccine efficacy variant virus
[DOI] 10.15585/mmwr.mm7131a2 PMC 바로가기 [Article Type] Article

Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

Favipiravir 및/또는 nitazoxanide: IMSS(FANTAZE)에서 치료를 받는 의료 종사자, 가족 구성원 및 환자를 대상으로 한 COVID-19 조기 치료에 대한 무작위, 이중 맹검, 2x2 설계, 위약 대조 시험

Randomized Controlled Trial

Published on 2022-07-222022-09-11
Journal: Trials
[Category] COVID19(2023년), SARS, 임상, 치료제,

[키워드] 1:1 2×2 design absence Admission antimicrobial Antimicrobials Antiviral effect antiviral therapy Antiviral treatment antivirals appear assigned Asymptomatic blinded to treatment combination therapy Comorbidities Comorbidity Controlled trial COVID-19 COVID-19 disease disease double-blind early disease early phase early treatment example Favipiravir followed by Gender Genetic genetic mutation Health high risk Hospitalization Hypothesis in some include individuals Infection Inflammatory Influenza intensive care investigator investigators later phase morbidity and mortality Mutation mutation rate nitazoxanide obesity older patient outcome pandemic participant patients treated pharmacokinetics phase phase IIa Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial positive presence or absence Prevent Primary outcome progression protocol randomised randomised controlled trial Randomised controlled trial. Randomized receive replicates SARS-CoV-2 secondary Secondary outcomes security Sepsis severe disease smoking status Social Security Stratification symptomatic symptomatic COVID-19 Symptoms tested the disease therapy those with comorbidity Toxicity treatment allocation Trial upper respiratory tract Viral load virus
[DOI] 10.1186/s13063-022-06533-0 PMC 바로가기 [Article Type] Randomized Controlled Trial

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

5~11세 어린이의 오미크론에 대한 BNT162b2 백신 효과

Article

Published on 2022-07-212022-09-11
Journal: The New England Journal of Medicine
[Category] COVID19(2023년), SARS, 변종, 진단, 치료법,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age BNT162b2 BNT162b2 vaccine calculated Care children Cohort Control controls coronavirus coronavirus disease Coronavirus disease 2019 cumulative cumulative incidence dominant variant dose Effectiveness eligible European event Evidence first dose Health Health care incidence Infection Kaplan-Meier estimator Limited Messenger RNA moderate of BNT162b2 omicron Omicron variant outcome provided risk risk difference risk ratio RNA vaccine SARS-CoV-2 SARS-COV-2 infection second dose severe acute respiratory syndrome Coronavirus study group study groups study period subgroups symptomatic COVID-19 the study group the vaccine union Vaccine vaccine doses Year
[DOI] 10.1056/NEJMoa2205011 PMC 바로가기 [Article Type] Article

COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland

Delta AY.4.2의 증상이 있는 SARS-CoV-2 감염 및 심각한 COVID-19 결과에 대한 COVID-19 백신 효과: 스코틀랜드의 540만 개인에 대한 코호트 및 테스트 음성 연구

Article

Published on 2022-07-092022-09-11
Journal: Journal of Global Health
[Category] COVID19(2023년), SARS, 변종, 치료기술,

[키워드] 95% CI 95% confidence interval accounted acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adults age BNT162b2 ChAdOx1 Chain Reaction cohort study Community conditions conducted confounders contributed coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 admission COVID-19 hospitalisation COVID-19 vaccine Cox proportional hazard Cox proportional hazards model death Delta Effectiveness enhanced Good hazard ratio Hospital admission increased risk individual individuals Infection Lineage mRNA mRNA-1273 mRNA-1273 vaccine mRNA-1273 vaccines offered omicron Omicron variant outcome performed platform polymerase chain polymerase chain reaction proportional hazards model provided reverse transcriptase Reverse transcriptase polymerase chain reaction RT-PCR SARS-CoV-2 SARS-COV-2 infection second vaccination security severe acute respiratory syndrome Coronavirus severe COVID-19 Sex socioeconomic status spline splines symptomatic symptomatic COVID-19 symptomatic infection symptomatic SARS-CoV-2 infection transcriptase United Kingdom vaccination Vaccine vaccine dose Vaccines variant variant of SARS-CoV-2 were infected
[DOI] 10.7189/jogh.12.05025 PMC 바로가기 [Article Type] Article

Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design

스코틀랜드의 증후성 질환에 대한 백신 부스터의 우려 및 효과에 대한 오미크론 변이의 심각도(EAVE II): 중첩 테스트 음성 디자인을 사용한 국가 코호트 연구

Article

Published on 2022-07-012022-09-11
Journal: The Lancet. Infectious Diseases
[Category] COVID19(2023년), SARS, 변종,

[키워드] 95% CI adjusted Admission booster booster dose Booster vaccine booster vaccines Care case-control study cohort analysis cohort study core COVID-19 defined Delta VOC dose dose of vaccination Edinburgh effective Effectiveness enhanced estimate Health Data Research UK Hospital admission hospitalisation individual individuals Infection initial Innovation laboratory data National offer omicron Omicron variant outcome platform positive positive RT-PCR proportion Public reduction in Reinfection risk risk of COVID-19 S-gene SARS-COV-2 infection Scottish severity Spread symptomatic symptomatic COVID-19 symptomatic disease symptomatic infection symptomatic SARS-CoV-2 infection tested the SARS-CoV-2 university vaccination Vaccine vaccine dose VoC with infection
[DOI] 10.1016/S1473-3099(22)00141-4 PMC 바로가기 [Article Type] Article

Saliva versus Upper Respiratory Swabs: Equivalent for Severe Acute Respiratory Syndrome Coronavirus 2 University Screening while Saliva Positivity Is Prolonged After Symptom Onset in Coronavirus Disease 2019 Hospitalized Patients

타액 대 상부 호흡기 면봉: 중증 급성 호흡기 증후군 코로나바이러스 2 대학 선별 검사에 해당하며 코로나바이러스 질병 2019 입원 환자의 증상 발병 후 타액 양성이 연장됨

Article

Published on 2022-07-012022-09-11
Journal: The Journal of molecular diagnostics : JMD
[Category] COVID19(2023년), SARS, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Asymptomatic Cohort collected comparable coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 equivalent faculty hospital hospitalized patient hospitalized patients nare offer Onset pandemic populations positive Prolonged proportion Real-time PCR reopening respiratory Saliva SARS-CoV-2 SARS-CoV-2 detection School Schools Screening screening methods sensitivity severe acute respiratory syndrome Coronavirus specimen study cohort Swab symptom onset symptomatic symptomatic and asymptomatic symptomatic COVID-19 tested university University of Pennsylvania upper upper respiratory
[DOI] 10.1016/j.jmoldx.2022.03.012 PMC 바로가기 [Article Type] Article

Covid-19 vaccines and variants of concern: A review

Covid-19 백신 및 우려 변종: 검토

Review

Published on 2022-07-012022-09-11
Journal: Reviews in Medical Virology
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad5-nCoV administration adverse event AZD1222 BBIBP-CorV BNT162b2 caused Cell-mediated immunity Clinical studies CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 disease COVID-19 vaccination COVID-19 vaccines CVnCoV deaths effective vaccine Efficacy Infection mRNA mRNA vaccines mRNA-1273 Mutation nCoV Neutralising Antibodies neutralising antibody nine NVX-CoV2373 outbreak rare adverse events reported Research respiratory SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus Spike protein Spread symptomatic COVID-19 symptomatic COVID-19 disease the SARS-CoV-2 vaccination Vaccine vaccine candidate vaccine candidates vaccine efficacy variant variants variants of concern variants of concern. Viral Viral vector viral vector and mRNA vaccines VOCs Wuhan-Hu-1 ZF2001
[DOI] 10.1002/rmv.2313 PMC 바로가기 [Article Type] Review

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19

Covid-19 예방을 위한 근육주사 AZD7442(Tixagevimab-Cilgavimab)

Clinical Trial

Published on 2022-06-092022-09-11
Journal: The New England Journal of Medicine
[Category] COVID19(2023년), MERS, SARS, 비임상, 신약개발, 임상, 진단, 치료제,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adverse event adverse events age animal models assigned AstraZeneca breath cilgavimab Combination composed conducted coronavirus coronavirus disease Coronavirus disease 2019 Critical death dose Efficacy efficacy end point end point enrolled exposure to Follow-up Human incidence increased risk intramuscular injections median Mild moderate Neutralizing antibodies neutralizing antibody occurred participant pharmacokinetic data phase 3 trial Placebo placebo group prevention primary analysis Prophylactic randomization Randomized Randomly receive Relative risk reported respiratory response to vaccination risk reduction saline placebo SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severity shown single dose symptomatic COVID-19 the placebo group therapeutic effect Tixagevimab
[DOI] 10.1056/NEJMoa2116620 PMC 바로가기 [Article Type] Clinical Trial